The human cannabinoid G-protein-coupled receptors (GPCRs) CB1 and CB2 mediate the functional responses to the endocannabinoids anandamide and 2-arachidonyl glycerol (2-AG) and to the widely consumed plant phytocannabinoid Δ 9 -tetrahydrocannabinol (THC) 1 . The cannabinoid receptors have been the targets of intensive drug discovery efforts, because modulation of these receptors has therapeutic potential to control pain 2 , epilepsy 3 , obesity 4 , and other disorders. Although much progress in understanding the biophysical properties of GPCRs has recently been made, investigations of the molecular mechanisms of the cannabinoids and their receptors have lacked high-resolution structural data. Here we report the use of GPCR engineering and lipidic cubic phase crystallization to determine the structure of the human CB1 receptor bound to the inhibitor taranabant at 2.6-Å resolution. We found that the extracellular surface of CB1, including the highly conserved membrane-proximal N-terminal region, is distinct from those of other lipid-activated GPCRs, forming a critical part of the ligand-binding pocket. Docking studies further demonstrate how this same pocket may accommodate the cannabinoid agonist THC. Our CB1 structure provides an atomic framework for studying cannabinoid receptor function and will aid the design and optimization of therapeutic modulators of the endocannabinoid system. The endocannabinoid signalling system in mammals comprises endogenous lipid messengers (anandamide and 2-AG) and two homo logous GPCRs (CB1, which is located in the nervous system and periphery, and CB2, which is expressed primarily in immune cells) 1 . Human CB1 and CB2 (which share 42% sequence identity) are also activated by natural products 5 such as THC and by synthetic cannabinoids and can be inhibited by diverse subtype-selective and non-selective antagonists and inverse agonists 6 . CB1 is the most abundant GPCR in the central nervous system (CNS) and regulates diverse brain functions and behaviours, modulating neurotransmitter release and neuronal excitation through the pre-synaptic activation of the G-protein G i/o (inhibiting adenylate cyclase), GIRK channels, and arrestin/MAP kinase signalling 7 . Endocannabinoids are synthesized postsynaptically by lipases and travel across synapses in a retrograde manner 8 , embedding in the presynaptic membrane where they can activate CB1 9 . Beyond the CNS, CB1 signalling in peripheral tissues has been implicated in other physiological mechanisms such as release of the metabolic hormones leptin and insulin 10,11 . However, the mechanism by which lipidic or lipophilic cannabinoid agonists access their GPCR-binding sites and promote receptor activation through specific binding interactions is, as yet, unknown.
taranabant have proven effective in the clinic for treatment of obesity, but have failed to secure regulatory approval owing to adverse CNS side effects 13 . Peripheral blockade of CB1 by non-penetrant inverse agonists may represent an alternative therapeutic strategy for treating obesity, while avoiding CB1 receptors in the CNS 10 . Natural and synthetic cannabinoid ligands have also shown considerable promise in the treatment of neuropathic pain 2 and epilepsy-induced seizures 3 . To gain further insight into the molecular mechanisms of cannabinoid system modulators and aid structure-based ligand design, we sought to crystallize the human CB1 receptor and solve its atomic structure.
Obtaining diffraction-quality crystals of CB1 required optimization of both the construct and the purification technique. We carried out differential scanning fluorimetry on the detergent-solubilized receptor, which identified the inverse agonist taranabant as a ligand conferring enhanced thermostability (Methods and Extended Data Fig. 1 ). To promote lipidic cubic phase (LCP) crystallization, we replaced the third intracellular loop (ICL3) of CB1 with the thermostable PGS (Pyrococcus abyssi glycogen synthase) domain, which recently proved essential in helping solve crystal structures of the human orexin receptors 14 . We also incorporated the point mutation T210A, which was previously shown to stabilize the inactive conformation of CB1 and increase thermostability 15 . Finally, we truncated CB1(T210A)-PGS by eliminating the first 89 N-terminal residues and the C terminus after residue 421. The engineered construct binds to the inverse agonists taranabant and 1 Department of Biophysics, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA. 2 Green Center for Systems Biology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA. rimonabant (also denoted SR141716A) in a manner nearly identical to wild-type CB1. CB1(T210A)-PGS has, however, a sevenfold lower affinity for the agonist CP55940, consistent with stabilization of an inactive conformation (Extended Data Fig. 2 ) and in agreement with the original report of the T210A mutation 15 . After purifying this construct from Sf9 insect cells (Methods and Extended Data Fig. 3 ), we obtained LCP microcrystals that diffracted to 2.6 Å resolution, solved the structure by molecular replacement and refined the structure to an R free value of 0.23 (Methods and Extended Data Table 1 ). In the monoclinic crystals, CB1(T210A)-PGS packs in a manner such that the extracellularfacing ligand-binding region is not involved in lattice contacts (Extended Data Fig. 4a ), and the receptor and ligand are well ordered with low overall B factors. Although truncation of the N terminus of CB1 was necessary to form diffraction-quality crystals, such modifications may affect the functional properties of the receptor, as indicated by the variable expression and pharmacology of tissue-specific splice variants in this region 16 . Nevertheless, our binding data (Extended Data Fig. 2 ) and previous precedent 17 show that the basic inverse-agonistand agonist-binding properties of CB1 are maintained in a receptor lacking the N-terminal 89 residues (which also contains three consensus N-linked glycosylation motifs).
The global structure of the CB1 receptor, with its classical seventransmembrane fold, is shown in Fig. 1 . Using other rhodopsin family (class A) GPCRs as guides 18 , the taranabant-bound CB1 structure represents an inactive conformation with respect to G-protein binding, with a canonical ionic lock formed between Arg214 3.50 and Asp338 6.30 (distance, 3.4 Å; Ballesteros-Weinstein numbering used in superscript). At the extracellular surface, the second extracellular loop (ECL2) and the membrane-proximal N-terminal region preceding transmembrane domain 1 (TM1) form a lid over the orthosteric pocket, which almost completely shields taranabant from the solvent (Fig. 1a, b ). As is observed in the structure of the lipid-activated GPCR S1P 1 (ref. 19 ), a gap between TM1 and TM7 in the extracellular leaflet ( Fig. 1b ) may contribute to a membrane-embedded access channel for lipophilic agonists. Further dilation of the highly conserved residues (Ile119 1.35 , Phe381 7.37 , and Met384 7.40 ) that line this channel (Extended Data Fig. 5 ) would be required to facilitate entry of ligands. Previous molecular dynamics simulations proposed that the endocannabinoid 2-AG enters into the homologous CB2 receptor between TM6 and TM7 (ref. 20); however, these two transmembrane domains are tightly associated in the present structure. Taranabant makes multiple contacts with both TM1 and TM7 and fills the orthosteric pocket directly inside the TM1-TM7 opening, potentially acting as a plug that blocks entry of the endocannabinoid. The extracellular face and lid above the orthosteric pocket contain an abundance of acidic residues, giving a negatively charged surface that will energetically disfavour interaction with negatively charged ligands ( Fig. 1c ). This feature of CB1 may help to ensure lipid-binding selectivity in a bilayer containing a high concentration of negatively charged phospholipids.
The first part of the N terminus of CB1 observed in the electron density of our crystals begins at E100. The 13 membrane-proximal amino acids that precede TM1 fold over the ligand-binding pocket and interact with TM2, TM3, ECL2, and TM7 ( Fig. 2a, b ). This region is highly conserved in CB1 (Extended Data Fig. 6 ) and contributes extensively to interaction with taranabant (as will be discussed). The occluded nature of the CB1 orthosteric pocket was predicted by a study showing that disulfide bond formation between Cys98 and Cys107 modulates orthosteric ligand binding 21 ; however, this disulfide bond is either not present or not visible in the current structure (possibly owing to cysteine capping by iodoacetamide). To assess the flexibility of the N-terminal region of CB1, we carried out a 60-ns molecular dynamics simulation of the CB1 structure embedded in an explicit POPC bilayer in the presence and absence of taranabant. In both cases, the N-terminal region was highly stable over the course of the simulation, exhibiting low root mean squared deviation (r.m.s.d.) values comparable to those of the entire transmembrane bundle (Extended Data Fig. 7 ). These results support the idea that the N-terminal region of CB1 will maintain a conformation similar to the structure observed here, even in the absence of ligand. Other lipid-activated GPCRs that have been structurally characterized (S1P 1 and LPA 1 ; refs 19 and 22, respectively) contain a disulfide-cross-linked ECL2 structure that is very similar to that of CB1; however, the N-terminal regions of these receptors are markedly different, containing α -helices that sit above the membrane and pack between ECL1 and ECL2 ( Fig. 2c, d ). The occluded orthosteric pocket of CB1, with the N-terminal region folding over the buried hydrophobic inverse agonist taranabant, is mirrored in the structure of the visual photoreceptor rhodopsin bound to 11-cisretinal 23 (Fig. 2e ). A gap between TM1 and TM7 was proposed as part of a channel for uptake and release of the lipophilic 11-cis-retinal ligand, based on the structure of the ligand-free opsin in an active conformation 24 , further paralleling the structure of CB1. The opsin residues Leu40 1.35 , Ile290 7.37 , and Phe293 7.40 surrounding this gap are analogous to CB1 residues Ile119 1.35 , Phe381 7.37 , and Met384 7.40 (Extended Data Fig. 5 ).
Taranabant is a subtype-selective inverse agonist with an inhibition constant (K i ) of 0.13 nM for CB1 and a K i of 170 nM for CB2 (ref. 25) . Unambiguous electron density at the orthosteric ligand-binding pocket (Extended Data Fig. 4b , c) placed taranabant at an unusual site, towards TM1 and TM7, contrasting with the space occupied by inhibitors of other class A GPCRs, such as the β 2 adrenergic receptor 18 (Fig. 3a ). Taranabant adopts a conformation in which the chlorophenyl moiety extends towards TM5, the cyanophenyl buries deeper into the seven transmembrane bundle and the trifluoromethylpyridine projects into the putative access channel between TM1 and TM7 ( Fig. 3b ). Residues 100-112 are shown as orange sticks, and taranabant is shown as magenta spheres. The remainder of CB1 is depicted as a teal solvent-accessible surface. b, The extracellular region of CB1, with the receptor as a teal cartoon and taranabant as magenta sticks. c, The S1P 1 receptor (PDB accession number 3V2Y) is depicted as a blue cartoon, from the same perspective as in a after superposition with CB1. The ML056 antagonist is shown as blue sticks. d, The LPA1 receptor (PDB accession number 4Z35) as a salmon cartoon, from the same perspective as in a after superposition with CB1. The ONO 9910539 antagonist is shown as salmon sticks. e, The GPCR rhodopsin (PDB accession number 1F88) as a grey cartoon, from the same perspective as in a after superposition with CB1. The 11-cis-retinal inverse agonist ligand is shown as cyan sticks. Glycosyl moieties in the N-terminal region are removed for clarity.
The orthosteric binding pocket of CB1 is highly hydrophobic, as is expected for a lipid-activated receptor. Of the 24 residues within 4 Å of the ligand, there are only three polar side chains: Asp104, whose acidic side chain points towards the extracellular space; Ser123 1.39 near the access channel that forms a polar contact with the trifluoromethyl group of taranabant; and Ser383 7. 39 , which has been implicated in agonist binding 26 . By contrast, a large number of hydrophobic resi dues (including six Phe, three Met, two Trp, three Leu, and three Ile side chains) line the orthosteric pocket and make a variety of hydrophobic contacts with taranabant, burying 1,109 Å 2 of surface area (Fig. 3b ). All of the taranabant contact residues on CB1 are absolutely conserved across the vertebrate lineage, with the exception of Ile105, which can be replaced by Met (Extended Data Fig. 8 ). The major divergence between CB1 and CB2 within the subset of binding residues lies in the membrane-proximal N-terminal region, where Phe102, Met103, Asp104, Ile105, and Phe108 make van der Waals contacts with taranabant. The subtype selectivity of taranabant for CB1 may arise from the divergence of this region between CB1 and CB2.
Taranabant (Fig. 3a) and rimonabant ( Fig. 4a ) have related chemical structures and similar conformational properties in isolation 27 . Docking of rimonabant with the CB1 crystal structure yielded a lowenergy pose that overlaps almost completely with that of taranabant, contacting the same constellation of residues ( Fig. 4a ). This supports the use of the current structure to analyse the binding modes of both ligands. Mutagenesis studies have identified several residues whose mutation caused a loss in taranabant and/or rimonabant binding affinity [27] [28] [29] [30] . Indeed, many of these residues are in contact with the ligand in the CB1 structure, including Phe170 2.57 , Phe174 2.61 , Leu193 3.29 , Trp279 5.43 , Trp356 6.48 , Phe379 7.35 , and Leu387 7.42 . However, several residues on TM3 and TM5 (for example, Lys192 3.28 , Phe200 3.36 , and Tyr275 5.39 ) are not within contact distance of taranabant and appear to make indirect contributions to binding, through structural stabilization or influence of the conformational equilibrium of CB1.
To gain insight into the initial recognition of agonists by the CB1 receptor, we docked THC (a partial agonist 5 ) into our crystal structure coordinates using the program Glide (see Methods). The top docking poses have the tricyclic core of THC binding between TM1, TM2 and TM7 (as with taranabant), with the C3 alkyl chain overlapping with the chlorophenyl moiety of taranabant and extending towards Trp356 6.48 (Fig. 4b ). Conformational changes in this residue and its surroundings have been proposed as a trigger for CB1 activation, and mutation to alanine leads to enhanced stimulation (E max ) by CB1 agonists 31 . Previous mutagenesis experiments have also identified Phe174 2.61 , Leu193 3.29 , and Ser383 7.39 as important residues for binding of THC or related agonists such as CP55940 (refs 26, 32) . These residues are either in contact with or in close proximity to the preferred docking pose of THC. One caveat to these calculations is that the inactive structure of CB1 is not ideal for predicting high-affinity agonist interactions. It should, however, be noted that the crystallization construct (stabilized in an inactive conformation) still displays significant affinity for CP55940 (Extended Data Fig. 2 ). Finally, Cys355 6.47 on the bilayerfacing side of TM6 was reported to form a covalent adduct with a THC analogue that possesses a reactive group at the end of the C3-pentyl chain 33 . Starting with our THC pose, such cross-linking would require rotation of TM6 at the orthosteric pocket during CB1 activation and consequent disruption of the packing around Trp356 6.48 .
While our manuscript was under review, a crystal structure of human CB1 was reported 34 bound to the antagonist AM6538, which closely resembles rimonabant but has a nitrate group substituted on 'arm 2' of the rimonabant core (that is, the chlorophenyl moiety in Fig. 4a ). Although the taranabant-bound crystal structure reported here and the AM6538-bound structure are in general agreement (Extended Data Fig. 9a ), there are several differences that may be important for functional interpretation and prediction. Notably, the electron density for the ligand and the important N-terminal region is weak in the AM6538bound structure, with high B factors in the refined model (average B = 134.3 Å 2 for residues 99-112 and B = 119.5 Å 2 for the ligand). By contrast, the equivalent region in our taranabant-bound structure is very well ordered, with good density and much lower B factors (average B = 61.7 Å 2 for residues 100-112 and B = 42.0 Å 2 for the ligand) (Extended Data Fig. 9b, c) . The lack of clear density and resulting model ambiguity for the N-terminal region in the AM6538-bound structure may limit its utility for predicting the binding modes of other ligands. This is apparent in the erroneous docking prediction for taranabant, in which arm 1 and arm 2 (chlorophenyl and cyanophenyl groups) are swapped relative to their experimentally determined binding positions reported herein. Further biochemical and computational studies will be required to establish the relative utility of these two crystal structures as templates for ligand docking and design. GPCRs adopt multiple conformations, creating a complex energy landscape that allows the binding of different ligands to modulate different intracellular effectors, such as G proteins and arrestin 35 . CB1 has considerable agonist-independent constitutive activity 36 and exhibits subtle and paradoxical pharmacological properties; it is anta gonized by cannabidiol (a molecule that, but for a bond disconnection, is near-identical to THC) 5 and inhibited by the compound ORG27569, which allosterically increases agonist affinity but decreases subsequent receptor activation 37 . Understanding these phenomena will require additional structures of CB1 in different conformational states, bound to a range of ligands (both orthosteric and allosteric) of differing efficacy. Our structure of CB1 bound to taranabant represents a step in this direction and provides a crystallographic basis for computational design of cannabinoid system modulators.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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MethOds
Cloning, expression and purification. The wild-type human CB1 receptor gene (Uniprot Entry: P21554) was cloned into a modified pFastBac (Invitrogen) baculovirus expression vector with the haemagglutinin (HA) signal sequence followed by a Flag epitope tag at the N terminus and a 10× His-tag at the C terminus.
To facilitate receptor crystallization, the 76 N-terminal residues were removed, a TEV protease recognition site was introduced before residue Lys90, and the 51 C-terminal residues were deleted (truncation after Pro421). Residues 302-332 in the CB1 intracellular loop 3 (ICL3) were replaced with a synthetic DNA fragment containing the 196-amino acid coding sequence of P. abyssi glycogen synthase (PDB accession number: 2FBW). Finally, the mutation T210A was introduced by an adapted Multi-site Quickchange protocol (Stratagene). The final CB1(T210A)-PGS fusion construct was transfected into DH10Bac to produce a recombinant baculovirus with the Bac-to-Bac system (Invitrogen). The recombinant baculovirus was used to infect Sf9 insect cell culture at a cell density of 2.5 × 10 6 cells per ml −1 , with 1 μ M taranabant (Tocris) added to the medium. Infected cells were grown for 60 h at 27 °C before harvesting, and the cell pellets were stored at − 80 °C for future use.
Sf9 cell membranes were disrupted by thawing frozen cell pellets in a hypotonic buffer containing 10 mM Tris pH 7.5, 1 mM EDTA, 160 μ g ml −1 benzamidine, 100 μ g ml −1 leupeptin, 2 mg ml −1 iodoacetamide and 1 μ M taranabant. The cell membranes were centrifuged at 10,000 g for 20 min at 4 °C. Membrane pellets were solubilized in a buffer containing 50 mM HEPES, pH 7.5, 500 mM NaCl, 1% (w/v) n-dodecyl β -d-maltopyranoside (DDM; Anatrace), 0.2% sodium cholate, 0.2% cholesteryl hemi-succinate (CHS), 10% glycerol, 160 μ g ml −1 benzamidine, 100 μ g ml −1 leupeptin, 2 mg ml −1 iodoacetamide and 10 μ M taranabant for 1 h at 4 °C. The supernatant was isolated after ultra-centrifugation for 30 min at 100,000g and incubated with Ni-NTA agarose beads (GE Healthcare) in batch for 3 h at 4 °C. After binding, the beads were collected by centrifugation at 100g and washed with five volumes of Ni-NTA wash buffer (50 mM HEPES, pH 7.5, 500 mM NaCl, 0.05% (w/v) DDM, 0.01% sodium cholate, 0.01% CHS, 10% glycerol, 50 mM imidazole, 160 μ g ml −1 benzamidine, 100 μ g ml −1 leupeptin and 1 μ M taranabant). After transfer to a gravity column, beads were washed with 15 column volumes of Ni-NTA wash buffer, and receptor protein was eluted in Ni-NTA wash buffer with 200 mM imidazole and 2 mM calcium. The eluted protein was then loaded by gravity flow over anti-Flag M1 affinity resin. Detergent was exchanged from 0.05% DDM to 0.05% lauryl maltose neopentyl glycol (LMNG) on the M1 resin. Finally the pure receptor was eluted with 0.2 mg ml -1 Flag peptide and 5 mM EDTA. TEV protease (1:10 w/w) and PNGase F were added to the eluate, and protein was incubated at 4 °C overnight. Finally, the receptor was run on a Superdex 200 size-exclusion column (GE Healthcare) with buffer containing 20 mM HEPES, pH 7.5, 150 mM NaCl, 0.05% LMNG, and 1 μ M taranabant. Differential scanning fluorimetry. Protein samples were purified and prepared in the absence of ligand (apo), with taranabant, or with rimonabant, as described above. Differential scanning fluorimetry assays were performed in 96-well PCR plates using a real-time PCR machine (CFX96, Bio-Rad). Standard assay conditions (25 μ l) were 25 mM HEPES pH 7.5, 150 mM NaCl, 0.01% LMNG, 0.002% CHS and 10 μ M of the corresponding ligands. The protein concentration was 2 μ M and the BODIPY FL-l-cystine dye 38 was added at 2 μ M final concentration. All reactions were incubated at 4 °C for 20 min before scanning in the PCR machine. The fluorescence was measured at 0.5 °C temperature intervals from 4 °C to 90 °C by using the FAM filter set (450-490 nm excitation, 515-530 nm emission). Crystallization. Purified receptor was concentrated to 55 mg ml −1 using a 100-kDa cut-off Vivaspin column (Sartorius), and crystallized using the LCP method. The concentrated receptor was reconstituted into a lipid mixture containing monoolein plus 10% (w/w) cholesterol (Sigma), at a ratio of 2:3 receptor to lipid (by weight). Mixing was performed at room temperature using a syringe mixing apparatus as previously described 39 . The mesophase was dispensed in 40-nl drops onto 96-well glass plates and overlaid with 800 nl precipitant solution using a Gryphon LCP robot (Art Robbins Instruments). Crystals grew to full size after 2 weeks at 20 °C in the following overlay precipitant condition: 31% PEG 400, 100 mM sodium citrate pH 5.5, 100 mM magnesium sulfate. The crystals were harvested from LCP setups using MiTeGen loops and cryoprotected in liquid nitrogen. Data collection and processing. X-ray diffraction data were collected at GM/CA-CAT beamline 23ID-B at the Advanced Photon Source (APS), Argonne National Laboratory, equipped with an Eiger 16M detector. Datasets were acquired using a beam size of 20 μ m with 1.033-Å wavelength X-rays. For each crystal, fifty 0.4° oscillation images were collected, with 1-s exposure and without attenuation of the beam. Owing to radiation damage of crystals, a 97% complete diffraction data was merged from 42 crystals and scaled using HKL3000 40 . The dataset was processed in space group P2 1 , and a resolution cut-off of 2.6 Å was selected by examining CC 1/2 values after anisotropy correction in HKL3000. Structure determination and refinement. The structure of CB1(T210A)-PGS in complex with taranabant was solved by molecular replacement with Phaser 41 using human S1P 1 receptor 19 (PDB: 3V2Y) and PGS 42 (PDB: 2BFW) as independent search models. The solution was improved through iterations of manual building in Coot 43 , followed by refinement using Refmac5 (ref. 44) . Translation-librationscrew refinement was used to model atomic displacement factors. Refinement parameters for the taranabant ligand were generated using the PRODRG 45 web server. The resulting statistics for data collection and refinement are included in Extended Data Table 1 . The final structure had 96.6% of residues in the favoured region of the Ramachandran plot, 3.4% in the allowed region, and 0 residues disallowed. Figures were prepared using Pymol (Schrodinger LLC). The electrostatic potential surface shown in Fig. 1c was calculated using APBS 46 . Binding of ligands to the CB1 receptor. Ligand-binding experiments on membranes containing CB1 wild-type, CB1-PGS, and CB1(T210A)-PGS were carried out based on a previously published protocol 28 . Sf9 cells expressing each construct (without any ligand present) were used to generate membranes by Dounce homogenization and differential centrifugation 18 . Saturation binding was carried out by incubating 1.5-5 μ g of membranes with different concentrations of [ 3 H]SR141716A (54 Ci mmol −1 ; Perkin-Elmer) between 0.05 and 25.6 nM in assay buffer (25 mM Tris pH 7.5, 5 mM MgCl2, 1 mM EDTA) containing 0.1% protease-free BSA in a final volume of 250 μ l per tube. Reactions were incubated at 30 °C for 1 h and then quenched with 250 μ l assay buffer with 5% BSA. Non-specific binding was determined using reactions containing 1 μ M unlabelled ligand. Reactions were separated on a vacuum manifold using GF/C filters (pre-soaked in assay buffer supplemented with 0.5% polyethylenimine) to retain membranes and discard unbound ligand. After washing four times with cold assay buffer, bound radioactivity was quantified using a scintillation counter. For competition-binding experiments, aliquots of membranes were incubated with 3 nM [ 3 H]SR141716A, and varying concentrations of competitor ligands (taranabant or CP55940) were included in the binding reactions. All binding experiments were carried out as three independent experiments, each performed in duplicate. Data analysis and fitting was performed with GraphPad Prism (GraphPad Software Inc.). Molecular dynamics simulations. The system used for molecular dynamics simulation consisted of one copy of CB1 receptor (PGS domain removed), taranabant, 240 POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) molecules, 48 Na + , 57 Cl − , and 17,087 water molecules. Molecular dynamics simulations were performed with periodic boundary condition to produce isothermal-isobaric ensembles using the modified PMEMD.CUDA program in AMBER 14 (ref. 47) . Temperature was regulated using Langevin dynamics 48 with a collision frequency of 5 ps −1 . Pressure was regulated using the isotropic position scaling algorithm with the pressure relaxation time set to 1.0 ps. The integration of the equations of motion was conducted at a time step of 1 fs for the relaxation phase and 2 fs for the equi librium and sampling phases. After a 5-ns equilibration, a 55-ns molecular dynamics simulation was performed at 298 K, 1 bar to produce constant temperature and pressure ensembles. The transmembrane helices were very stable in both simulations and the mean r.m.s.d. values were 1.52 ± 0.13 and 1.45 ± 0.23 Å for the apo and complex forms, respectively. The r.m.s.d. values of the membrane-proximal N-terminal region of the complex form (0.96 ± 0.24 Å) were smaller than those of the apo form (1.28 ± 0.19 Å). Docking of rimonabant and THC. Molecular docking was performed for taranabant, rimonabant, and THC using Glide 49, 50 , implemented in the Schrodinger software package (http://www.schrodinger.com). Different protocols of receptor preparation, grid generation and flexible ligand docking were evaluated and the one that produced the best docking scores was adopted. The optimal Glide protocol for CB1 included: only optimize hydrogen atoms in the receptor preparation; allow hydroxyl and thiol groups of Thr197, Ser383 and Cys386 to be rotatable; use the standard precision scoring function. We first tested our docking protocol by re-docking the taranabant ligand from the crystal structure. The best docking scores were − 12.76 and − 12.59 kcal mol −1 for the crystal conformation and a 3D conformation generated without any initial bias using the Concord program (http://www.certara.com), respectively. The r.m.s.d. between the crystal structure and docking pose was 0.55 Å for the Concord conformation. Next, the antagonist rimonabant and the partial agonist THC were docked to the binding pocket using the same protocol. The docking scores of the best docking poses were − 8.99 and − 9.36 kcal mol −1 for rimonabant and THC, respectively. Data availability. Atomic coordinates and structure factors for the reported crystal structure have been deposited in the Protein Data Bank (PDB) under the accession code 5U09. All other data are available from the corresponding author upon reasonable request. 
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